scholarly journals Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma

2016 ◽  
Vol 5 (11) ◽  
pp. e1238542 ◽  
Author(s):  
Shiro Suzuki ◽  
Jun Sakata ◽  
Fumi Utsumi ◽  
Ryuichiro Sekiya ◽  
Hiroaki Kajiyama ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Peptide Vaccine ◽  
Vaccine Therapy ◽  
Ovarian Clear Cell Carcinoma

scholarly journals Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy

2013 ◽  
Vol 10 (2) ◽  
pp. 338-343 ◽  
Author(s):  
Shiro Suzuki ◽  
Shiro Suzuki ◽  
Kiyosumi Shibata ◽  
Kiyosumi Shibata ◽  
Fumitaka Kikkawa ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Response ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Peptide Vaccine ◽  
Vaccine Therapy ◽  
Ovarian Clear Cell Carcinoma

scholarly journals Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 550
Author(s):  
Mayu Ukai ◽  
Akira Yokoi ◽  
Kosuke Yoshida ◽  
Shiro Suzuki ◽  
Kiyosumi Shibata ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Peptide Vaccine ◽  
Therapy Response ◽  
Predictive Biomarkers ◽  
Cancer Tissue ◽  
Ovarian Clear Cell Carcinoma ◽  
Serum Samples ◽  
Extracellular Mirnas

Ovarian clear cell carcinoma (OCCC) has been treated with surgery and chemotherapy; however, the prognosis remains poor because of chemoresistance. Therefore, immunotherapies are attracting attention, including the GPC3 peptide vaccine, which improves overall survival. However, the response rate is limited and there are no sufficient predictive biomarkers that can identify responders before treatment. Our purpose was to identify circulating serum miRNAs as predictive biomarkers for response to GPC3 peptide vaccine. Eighty-four patients in a phase II trial of a GPC3 peptide vaccine were enrolled and miRNA sequencing was performed on their serum samples. Candidate miRNAs were selected from a group of 14 patients for whom treatment was responsive and validated in an independent group of 10 patients for whom treatment was responsive. Three markedly upregulated miRNAs, miR-375-3p, miR-193a-5p, and miR-1228-5p, were identified, and the combination of those miRNAs demonstrated high value in the prediction of the response. The origin of these miRNAs was assessed by referring to OCCC tissue miRNA profiles, and they were not identified as cancer tissue-related miRNAs. Functional annotation analysis suggested that they were associated with interferon-related pathways. The miRNAs identified herein have great potential to allow the realization of liquid biopsy for predicting the immunotherapy response and precision medicine.

Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration

2020 ◽  
Vol 40 (12) ◽  
pp. 6791-6798
Author(s):  
MARIKO MIYAZAWA ◽  
MASANORI YASUDA ◽  
MASAKI MIYAZAWA ◽  
NAOKI OGANE ◽  
TOMOMI KATOH ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Hypoxia Inducible Factor ◽  
Carcinoma Cells ◽  
Ovarian Clear Cell Carcinoma ◽  
Hypoxia Inducible Factor 1Α

scholarly journals Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (39) ◽  
pp. 62925-62938 ◽  
Author(s):  
I-Ling Hsu ◽  
Cheng-Yang Chou ◽  
Yi-Ying Wu ◽  
Jia-En Wu ◽  
Chen-Hsien Liang ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cell Carcinoma ◽  
Cardiac Glycosides ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma

scholarly journals Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Huijuan Ge ◽  
Yaoxin Xiao ◽  
Guangqi Qin ◽  
Yanzi Gu ◽  
Xu Cai ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Tissue Microarrays ◽  
Ovarian Clear Cell Carcinoma ◽  
Repair Deficiency ◽  
Ovarian Epithelial Carcinoma ◽  
Histological Characteristics ◽  
Infiltrating Lymphocytes

Abstract Background Ovarian clear cell carcinoma (OCCC) is the second subtype of ovarian epithelial carcinoma reported to be closely related to Lynch syndrome (LS). ARID1A mutation is an important pathogenetic mechanism in OCCC that leads to loss of ARID1A expression in approximately half of OCCCs. However, the correlation of MMR status and ARID1A deficiency is unclear. The current study aimed to identify the clinical and histopathological characteristics of OCCC associated with dMMR and to further explore the association between dMMR and ARID1A deficiency. Methods A cohort of 176 primary OCCC patients was enrolled and review included histological characteristics (nuclear atypia, necrosis, mitosis, stromal hyalinization, and background precursors) and host inflammatory response (tumor-infiltrating lymphocytes, peritumoral lymphocytes, intratumoral stromal inflammation and plasma cell infiltration). Immunohistochemical staining of MLH1, PMS2, MSH2, MSH6 and ARID1A was performed using tissue microarrays. Results dMMR was detected in 10/176 tumors (6 %), followed by MSH2/MSH6 (6/176), MLH1/PMS2 (3/176), and MSH6 (1/176). The average age of patients with dMMR was younger than that of patients with intact MMR (46 y vs. 53 y). Tumors with diffuse intratumoral stromal inflammation remained significantly associated after multivariate analysis. ARID1A expression was absent in 8 patients with dMMR (8/10), which is a significantly higher frequency than that observed in patients with intact MMR (80 % vs. 43.2 %). Conclusions Our study indicates that diffuse intratumoral stromal inflammation of OCCCs is associated with dMMR, with loss of MSH2/MSH6 expression being most frequent. dMMR is strongly associated with the loss of ARID1A expression in OCCC.

Sign in / Sign up

Export Citation Format

Share Document